191 related articles for article (PubMed ID: 35577150)
1. Prolonged blood circulation outperforms active targeting for nanocarriers-mediated enhanced hepatocellular carcinoma therapy in vivo.
Wang YQ; Huang C; Ye PJ; Long JR; Xu CH; Liu Y; Ling XL; Lv SY; He DX; Wei H; Yu CY
J Control Release; 2022 Jul; 347():400-413. PubMed ID: 35577150
[TBL] [Abstract][Full Text] [Related]
2. Facile fabrication of a novel hybrid nanoparticles by self-assembling based on pectin-doxorubicin conjugates for hepatocellular carcinoma therapy.
Ye PJ; Huang C; Yang S; Gao P; Li ZP; Tang SY; Xiang Y; Liu YF; Chen YP; He DX; Yu CY
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S661-S670. PubMed ID: 30307317
[TBL] [Abstract][Full Text] [Related]
3. Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy
Xiang Y; Huang W; Huang C; Long J; Zhou Y; Liu Y; Tang S; He DX; Tan XW; Wei H; Yu CY
Mol Pharm; 2020 Sep; 17(9):3223-3235. PubMed ID: 32658485
[TBL] [Abstract][Full Text] [Related]
4. Erythrocyte-Cancer Hybrid Membrane Camouflaged Hollow Copper Sulfide Nanoparticles for Prolonged Circulation Life and Homotypic-Targeting Photothermal/Chemotherapy of Melanoma.
Wang D; Dong H; Li M; Cao Y; Yang F; Zhang K; Dai W; Wang C; Zhang X
ACS Nano; 2018 Jun; 12(6):5241-5252. PubMed ID: 29800517
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
6. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
7. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
[TBL] [Abstract][Full Text] [Related]
8. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment.
Zhang Z; Qian H; Huang J; Sha H; Zhang H; Yu L; Liu B; Hua D; Qian X
Int J Nanomedicine; 2018; 13():4961-4975. PubMed ID: 30214200
[TBL] [Abstract][Full Text] [Related]
9. Biodegradable Hypocrellin B nanoparticles coated with neutrophil membranes for hepatocellular carcinoma photodynamics therapy effectively via JUNB/ROS signaling.
Zhang Z; Li D; Cao Y; Wang Y; Wang F; Zhang F; Zheng S
Int Immunopharmacol; 2021 Oct; 99():107624. PubMed ID: 34343939
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
11. Erythrocyte membrane-camouflaged gefitinib/albumin nanoparticles for tumor imaging and targeted therapy against lung cancer.
Wen Q; Zhang Y; Muluh TA; Xiong K; Wang B; Lu Y; Wu Z; Liu Y; Shi H; Xiao S; Fu S
Int J Biol Macromol; 2021 Dec; 193(Pt A):228-237. PubMed ID: 34688683
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment-responsive versatile "Trojan horse" theranostic nanoplatform for magnetic resonance imaging-guided multimodal synergistic antitumor treatment.
Huang Q; Pan Y; Wang M; Liu Z; Chen H; Wang J; Zhao Z; Zhang Y
Acta Biomater; 2022 Jul; 147():270-286. PubMed ID: 35595202
[TBL] [Abstract][Full Text] [Related]
13. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
[TBL] [Abstract][Full Text] [Related]
14. Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma.
Ji B; Cai H; Yang Y; Peng F; Song M; Sun K; Yan F; Liu Y
Acta Biomater; 2020 Jul; 111():363-372. PubMed ID: 32434082
[TBL] [Abstract][Full Text] [Related]
15. A RBC membrane-camouflaged biomimetic nanoplatform for enhanced chemo-photothermal therapy of cervical cancer.
Luo L; Zeng F; Xie J; Fan J; Xiao S; Wang Z; Xie H; Liu B
J Mater Chem B; 2020 May; 8(18):4080-4092. PubMed ID: 32239064
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cell delivery and cell membrane camouflaged PLGA nanoparticles in the delivery of shikonin for colorectal cancer treatment.
Zhou J; Jiang Z; Sun R; Pan D; Du Q; Zhou X; Chen Y; Chen Y; Peng J
Colloids Surf B Biointerfaces; 2024 Jun; 241():114017. PubMed ID: 38865869
[TBL] [Abstract][Full Text] [Related]
17. Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma.
Ning Q; Liu YF; Ye PJ; Gao P; Li ZP; Tang SY; He DX; Tang SS; Wei H; Yu CY
ACS Appl Mater Interfaces; 2019 Mar; 11(11):10578-10588. PubMed ID: 30802029
[TBL] [Abstract][Full Text] [Related]
18. A minimalist cancer cell membrane-shielded biomimetic nanoparticle for nasopharyngeal carcinoma active-targeting therapy.
Sun S; Han R; Sun Y; Chen W; Zhao L; Guan X; Zhang W
Colloids Surf B Biointerfaces; 2024 Jun; 238():113909. PubMed ID: 38599076
[TBL] [Abstract][Full Text] [Related]
19. Biomimetic Targeted Theranostic Nanoparticles for Breast Cancer Treatment.
Marshall SK; Angsantikul P; Pang Z; Nasongkla N; Hussen RSD; Thamphiwatana SD
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235009
[TBL] [Abstract][Full Text] [Related]
20. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
